Bailey Jeffrey Allen's Form 4 filing
Aurinia Pharmaceuticals Inc. (AUPH) · filed Nov 12, 2024
- Accession no.
- 0001600620-24-000116
- Filed
- Nov 12, 2024
- Trade date
- Nov 8-11, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $38.4K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bailey Jeffrey AllenCIK 0001500210 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 8, 2024 | Common Stock | MOption exerciseAcquired | +17,913 | – | – | 17,913 | Direct | |
| Nov 11, 2024 | Common Stock | SSaleDisposed | −4,557 | $8.43 | −$38,415.51 | 13,356 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 8, 2024 | Common Stock | MOption exerciseDisposed | −17,913 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.